Me Cuido icon

2.0.0 by Boehringer Ingelheim International GmbH


Sep 26, 2018

About Me Cuido

MEcuido gives advice on COPD, type 2 diabetes and anticoagulation.

MEcuido is an application designed to ease the life of chronic patients and their caregivers and thus help them better adherence. It provides visual information and advice on chronic disease in general and COPD, type 2 diabetes and anticoagulation in particular.

With this application you can learn more about the disease, know the consequences of not caring properly and learn how treatments work. It also allows you to configure a system of alerts that notify you when to take medication (this configuration is automatic for certain chronic treatments). Also, if you follow the treatment correctly, it will encourage be consistent with motivational messages. The application offers a geolocation service to find the nearest pharmacies at all times and provides for certain treatments audioprospectos digitized.

In MEcuido you will find:

• General information on chronic diseases and specific information on Chronic Obstructive Pulmonary Disease (COPD), type 2 diabetes and anticoagulation

• Tips

• digitized Prospects: video + audio

• Augmented Reality

• automated alarms to take medication

• motivational messages

What's New in the Latest Version 2.0.0

Last updated on Sep 26, 2018

Actualización general de la aplicación

Translation Loading...

Additional APP Information

Latest Version

Request Me Cuido Update 2.0.0

Uploaded by

Rizani Rizani

Requires Android

Android 4.1+

Available on

Get Me Cuido on Google Play

Show More

Me Cuido Screenshots

Comment Loading...
Languages
Searching...
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.